Parkside Financial Bank & Trust’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.1K | Hold |
400
| – | – | ﹤0.01% | 2326 |
|
|
2025
Q4 | $1.48K | Hold |
400
| – | – | ﹤0.01% | 2210 |
|
|
2025
Q3 | $1.06K | Hold |
400
| – | – | ﹤0.01% | 2262 |
|
|
2025
Q2 | $395 | Sell |
400
-275
| -41% | -$275 | ﹤0.01% | 2624 |
|
|
2025
Q1 | $972 | Buy |
675
+275
| +69% | +$507 | ﹤0.01% | 2117 |
|
|
2024
Q4 | $880 | Hold |
400
| – | – | ﹤0.01% | 1764 |
|
|
2024
Q3 | $656 | Hold |
400
| – | – | ﹤0.01% | 1782 |
|
|
2024
Q2 | $880 | Hold |
400
| – | – | ﹤0.01% | 1677 |
|
|
2024
Q1 | $1.07K | Hold |
400
| – | – | ﹤0.01% | 1602 |
|
|
2023
Q4 | $1.2K | Hold |
400
| – | – | ﹤0.01% | 1581 |
|
|
2023
Q3 | $392 | Hold |
400
| – | – | ﹤0.01% | 1943 |
|
|
2023
Q2 | $560 | Sell |
400
-300
| -43% | -$419 | ﹤0.01% | 1885 |
|
|
2023
Q1 | $1.11K | Buy |
700
+300
| +75% | +$1.55K | ﹤0.01% | 1829 |
|
|
2022
Q4 | $2.49K | Hold |
400
| – | – | ﹤0.01% | 1605 |
|
|
2022
Q3 | $3K | Hold |
400
| – | – | ﹤0.01% | 1395 |
|
|
2022
Q2 | $3K | Hold |
400
| – | – | ﹤0.01% | 1425 |
|
|
2022
Q1 | $2K | Hold |
400
| – | – | ﹤0.01% | 1590 |
|
|
2021
Q4 | $2K | Hold |
400
| – | – | ﹤0.01% | 1599 |
|
|
2021
Q3 | $5K | Hold |
400
| – | – | ﹤0.01% | 1228 |
|
|
2021
Q2 | $8K | Hold |
400
| – | – | ﹤0.01% | 1037 |
|
|
2021
Q1 | $11K | Hold |
400
| – | – | ﹤0.01% | 900 |
|
|
2020
Q4 | $10K | Hold |
400
| – | – | ﹤0.01% | 874 |
|
|
2020
Q3 | $15K | Hold |
400
| – | – | 0.01% | 729 |
|
|
2020
Q2 | $21K | Hold |
400
| – | – | 0.01% | 626 |
|
|
2020
Q1 | $13K | Sell |
400
-100
| -20% | -$5.28K | ﹤0.01% | 661 |
|
|
2019
Q4 | $30K | Hold |
500
| – | – | 0.01% | 548 |
|
|
2019
Q3 | $18K | Hold |
500
| – | – | 0.01% | 648 |
|
|
2019
Q2 | $23K | Hold |
500
| – | – | 0.01% | 598 |
|
|
2019
Q1 | $20K | Hold |
500
| – | – | 0.01% | 600 |
|
|
2018
Q4 | $23K | Hold |
500
| – | – | 0.01% | 529 |
|
|
2018
Q3 | $22K | Hold |
500
| – | – | 0.01% | 583 |
|
|
2018
Q2 | $20K | Hold |
500
| – | – | 0.01% | 590 |
|
|
2018
Q1 | $36K | Sell |
500
-400
| -44% | -$29.4K | 0.01% | 414 |
|
|
2017
Q4 | $59K | Hold |
900
| – | – | 0.02% | 321 |
|
|
2017
Q3 | $45K | Hold |
900
| – | – | 0.02% | 364 |
|
|
2017
Q2 | $42K | Buy |
+900
| New | +$33.1K | 0.02% | 369 |
|
Other funds holding ESPR
WA
TSC
O
Parkside Financial Bank & Trust's ESPR Position: Q1 2026 in Review
Parkside Financial Bank & Trust held its Esperion Therapeutics (ESPR) position steady in Q1 2026 at 400 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.
Parkside Financial Bank & Trust first reported a position in ESPR in Q2 2017 and has held it in 36 quarters since. The position peaked at $59K in Q4 2017. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.
- Parkside Financial Bank & Trust held 400 shares of Esperion Therapeutics worth $1.1K as of Q1 2026.
- Parkside Financial Bank & Trust left its Esperion Therapeutics share count unchanged in Q1 2026.
- Esperion Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2326 holding.
- Parkside Financial Bank & Trust first reported a position in Esperion Therapeutics in Q2 2017 and has held it in 36 quarters since.
- Parkside Financial Bank & Trust's Esperion Therapeutics position peaked at $59K in Q4 2017.
- 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.
Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.